Accelerating the Development of Gamma Delta T Therapies to Deliver the Cell Therapies of the Future
The inaugural virtual Gamma Delta T Therapies Summit is the only industry dedicated forum focused on furthering the understanding of γδ T cells, driving clinical proof of concept, and scaling up manufacturing to deliver off-the-shelf gamma delta T therapies for oncological indications.
Join us virtually with over 100 of the key stakeholders from across pharma, biotech, and academia to discuss the precise mechanisms of γδ T cells, manufacturing considerations to ensure purity and quantity of cells, and the latest developments in γδ T therapies.
As we gather world leading researchers at the Gamma delta T Therapies Summit, learn how the industry is effectively manipulating and engineering gamma delta cells with antibody and cell-based approaches for improved safety, efficacy and manufacturability to bring to market effective Gamma Delta Therapies for patients in need.
Category: Conferences | Science, Health & Medicine
Speakers: Stewart Abbot CSO Adicet Bio, Christoph Baumann Principal Scientist & Cancer Biotherapeutics , Dilrukshi Nisansala Wisidagamage Don PhD Candidate Great Ormond Street Institute of Child Health, University College London, Marta Barisa Honorary Senior Research Fellow Great Ormond Street Institute of Child Health, University College London, Lawrence Lamb CSO Incysus Therapeutics, Emmanuel Scotet Research Director INSERM, Daniel Olive Head Tumour Immunology Marseille Cancer Research Center, Richard Lopez CEO & Founder PhosphoGam, Aleksandra Filipovic Head of Oncology PureTech Health, Dieter Kabeltiz Senior Research Group Leader UKSH Campus Kiel, Zsolt Sebestyen Associate Professor UMC Utrecht, David Vermijlen Associate Professor University of Brussels, Vicky Morrison Principal Investigator University of Glasgow, Bruno Silva-Santos Associate Professor University of Lisbon, Domenico Mavilio Associate Professor University of Milan, Massimo Massaia Associate Professor of Haematology University of Torino